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Background: Pseudohypoparathyroidism (PHP) is a rare disease whose phenotypic features are rather difficult to
identify in some cases. Thus, although these patients may present with the Albright’s hereditary osteodystrophy
(AHO) phenotype, which is characterized by small stature, obesity with a rounded face, subcutaneous ossifications,
mental retardation and brachydactyly, its manifestations are somewhat variable. Indeed, some of them present with
a complete phenotype, whereas others show only subtle manifestations. In addition, the features of the AHO
phenotype are not specific to it and a similar phenotype is also commonly observed in other syndromes.
Brachydactyly type E (BDE) is the most specific and objective feature of the AHO phenotype, and several
genes have been associated with syndromic BDE in the past few years. Moreover, these syndromes have a
skeletal and endocrinological phenotype that overlaps with AHO/PHP. In light of the above, we have developed an
algorithm to aid in genetic testing of patients with clinical features of AHO but with no causative molecular defect at
the GNAS locus. Starting with the feature of brachydactyly, this algorithm allows the differential diagnosis to be
broadened and, with the addition of other clinical features, can guide genetic testing.
Methods: We reviewed our series of patients (n = 23) with a clinical diagnosis of AHO and with brachydactyly type E or
similar pattern, who were negative for GNAS anomalies, and classify them according to the diagnosis algorithm to
finally propose and analyse the most probable gene(s) in each case.
Results: A review of the clinical data for our series of patients, and subsequent analysis of the candidate
gene(s), allowed detection of the underlying molecular defect in 12 out of 23 patients: five patients
harboured a mutation in PRKAR1A, one in PDE4D, four in TRPS1 and two in PTHLH.
Conclusions: This study confirmed that the screening of other genes implicated in syndromes with BDE
and AHO or a similar phenotype is very helpful for establishing a correct genetic diagnosis for those
patients who have been misdiagnosed with “AHO-like phenotype” with an unknown genetic cause, and
also for better describing the characteristic and differential features of these less common syndromes.
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Albright’s hereditary osteodystrophy (AHO) is a unique
phenotype classically associated with pseudohypoparathyr-
oidism (PHP) [1, 2]. This phenotype was initially described
by Albright et al. as a constellation of signs, including short
stature, obesity with a rounded face, subcutaneous ossifica-
tions, mental retardation and brachydactyly. Parathyroid
hormone (PTH) resistance was also originally included as a
feature of the AHO phenotype as these authors noticed a
reduced calcaemic and phosphaturic response to injected
bovine parathyroid extract in such patients with normal
renal function [1]. However, more patients with this
phenotype but lacking hormone resistance were described
in 1952, thus this disease was termed pseudopseudohypo-
parathyroidism (PPHP). Consequently, this type of hormo-
nal resistance was included as a non-obligatory
manifestation of AHO [3]. Many years later, genetic and/or
epigenetic alterations at the guanine nucleotide-binding
protein, alpha-stimulating (Gsα) locus (GNAS) were identi-
fied as the cause of this condition in about 70% of patients
with a clinical diagnosis of PHP/PPHP [4], or iPPSD2 (in-
activating PTH/PTHrP signalling disorder) and iPPSD3 ac-
cording to the new proposed classification [5].
Despite this high detection rate of GNAS molecular de-
fects, some patients with a clinical suspicion of PHP/PPHP
still lack a confirmed molecular diagnosis, possibly due to
the variability of the manifestations in terms of both num-
ber and severity, especially in cases in which there is no
family history ([5–7] and personal data). In addition, the
features of the AHO phenotype are not exclusive to PHP/
PPHP. For example, AHO-like syndrome, or brachydactyly
and mental retardation syndrome (BDMR, OMIM#60
0430), as its name indicates, includes a group of patients
who show several features of AHO (BDE and mental re-
tardation being the most notable) but with normal Gsα
levels and with no endocrine abnormality [8]. These pa-
tients frequently carry deletions at the 2q37 chromosome
or mutations in the gene coding for histone deacetylase 4
(HDAC4), which is found at this locus [8, 9]. Similarly, the
biochemical alterations (hypocalcaemia and hyperphospha-
temia) observed in PHP are also present in other syn-
dromes associated with calcium homeostasis, such as
hypoparathyroidism [10]. PTH resistance and brachydac-
tyly (but in a more severe form) are also present in acrody-
sostosis with multihormonal resistance ACRDYS1 (or
iPPSD4, OMIM#101800) [11–13], which is associated with
mutations in the gene coding for the cAMP-dependent
protein kinase type 1 regulatory subunit protein
(PRKAR1A) [14]. Another type of acrodysostosis, which
lacks hormone resistance (ACRDYS2 or iPPSD5,
OMIM#6146139), is caused by mutations in the gene cod-
ing for phosphodiesterase 4D (PDE4D) [15, 16].
Considering recent publications in which a significant
number of patients were clinically misdiagnosed as PHPwhen they actually had other syndromes [17], our goal
was to validate our diagnostic algorithm starting with
the brachydactyly feature to guide candidate gene testing
in patients with features of AHO who do not carry gen-
etic or epigenetic alterations at the GNAS locus.
Methods
Patients
The current series involved 23 out of a total of 149 pa-
tients referred to the Molecular (Epi)Genetics Labora-
tory at OSI Araba University Hospital for molecular
diagnosis with a clinical suspicion of AHO phenotype
with or without PTH resistance and the presence of bra-
chydactyly type E or a similar pattern. (Epi)genetic alter-
ations at the GNAS locus had been previously ruled out
as described [18].
The clinical details of the whole series studied are sum-
marized in Table 1. Some of these patients had already been
reported, as indicated in the Table 1. The clinical history of
the patients, including hand(s) (Additional files 1, 2 and 3:
Figures S1-S3) and feet radiographs and clinical photos (if
available), was requested from the physicians who referred
the samples for genetic study.
Candidate gene approach
The patients’ clinical features were reviewed to classify
them according to the brachydactyly pattern and other
clinical features, in accordance with the diagnostic algo-
rithm proposed by us previously [19] and updated to in-
clude the most recent findings (Figure 1). The most
probable candidate gene(s) were studied in each patient
(Additional file 4: Table S1).
The following disorders (all of which present BDE or
similar types) were considered: (i) iPPSD4 [14] and iPPSD5
[15, 16]; (ii) hypertension with brachydactyly syndrome or
iPPSD6 (HTNB, OMIM#112410), in which the responsible
gene, phosphodiesterase 3A (PDE3A), has been identified
very recently [20]; (iii) tricho-rhino-phalangeal syndrome
type I and III (TRPS-I, OMIM#190350; TRPS-III,
OMIM#190351), caused by mutations in the TRPS1 gene
[21] or the more severe form, type II (OMIM#150230),
which is a contiguous gene syndrome on 8q24.1 involving
loss-of-function copies of the TRPS1 and EXT1 genes [22];
(iv) BDMR; (v) brachydactyly type E with short stature,
PTHLH type (OMIM#613382), caused by mutations in the
gene coding for parathyroid hormone-related protein
(PTHLH) [23–25]; and (vi) isolated BDE in which the
HOXD13 gene has been implicated [26, 27].
We should mention at this point that, although Turner
syndrome chromosomal disorder (frequently, 45,X) is a
relatively well-known entity, patients also show BDE
[28] and short stature, which could give rise to some
misdiagnoses. However, none of our patients presented
clinical features compatible with Turner syndrome.
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Fig. 1 Updated clinical algorithm used during this project. Features in parentheses indicate that they are not obligatory features of the
syndromes. BDE: brachydactyly type E; MLPA: multiplex ligation-dependent probe amplification; MS-MLPA: methylation specific-MLPA; iPPSD:
inactivating PTH/PTHrP Signaling Disorder
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Genomic DNA was extracted from peripheral blood
mononuclear cells using the QIAamp DNA Mini Kit
(QIAGEN, Düren, Germany) according to the manufac-
turer’s instructions.
The DNA obtained was amplified by PCR for
PRKAR1A (ref: NM_002734), PDE4D (ref: NM_00110
4631), TRPS1 (ref: NM_014112), HDAC4 (ref: NM_006
037), PTHLH (ref: NM_198965.1) and/or HOXD13 (ref:
NM_000523) coding exons and exon–intron junction,
using specific primers (primers available on request).
Direct Sanger sequencing was carried out using standard
methods and an ABI 3500 Genetic Analyzer (Applied
Biosystems, Foster City, CA). The reference sequences
mentioned in parentheses were employed for mutation
description according to the HGVS nomenclature.Gene dosage analyses by multiplex ligation-dependent
probe amplification (MLPA)
Gene dosage analyses were carried out using the SALSA
MLPA P228-B1 TRPS1-EXT1, P179-B1 Limb− 1 and
P264 B1 Human Telomere 9 probemix (MRC-Holland,
Amsterdam, The Netherlands), when no alterations wereidentified by direct sequencing of the TRPS1 gene,
HOXD13 gene or HDAC4 gene, respectively.
Microsatellite analysis
2q37 deletions were studied by microsatellite analysis as
reported previously [29].
Results
Following the proposed candidate gene approach guided
by the aforementioned diagnostic algorithm, 12 out of
23 patients were diagnosed genetically.
Mutations in PRKAR1A in the current series: iPPSD4
Six patients with PTH resistance and severe, generalized
brachydactyly, both of which are typical characteristics
of iPPSD4 (classically called ACRDYS1), were identified.
Accordingly, the PRKAR1A gene was sequenced. Four of
these patients harboured the recurrent c.1101C>T/
p.Arg368* mutation (PHP01 and PHP02 already re-
ported [30], and PHP04 and PHP05) and a fifth one car-
ried the c.854A>G/p.Gln285Arg mutation (PHP03,
reported [30]). The functional impact of this substitution
was assessed experimentally and it was found to produce
a similar impairment to the recurrent mutation, i.e.,
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sensitivity to cAMP [30]. Parental studies suggested that
all mutations were de novo. The remaining patient had
no mutation in PRKAR1A.
Mutations in PDE4D in the current series: iPPSD5
In the patient (PHP06) with no mutation in PRKAR1A,
the other gene, PDE4D, associated with iPPSD5
(formerly named ACRDYS2) was sequenced. Initially
this patient presented elevated PTH (PTH = 107 pg/ml,
normal range: 10–65; 25-OH vitamin D = 13.9 ng/ml,
normal range 20–100), which is why iPPSD4 was sus-
pected. However, after vitamin D treatment her PTH
level normalized [31] (it was probably secondary to vita-
min D deficiency) [32]. A novel heterozygous mutation
(c.934C>G/p.Leu312Val) was identified in PDE4D. Func-
tional studies of this mutation confirmed its pathogen-
icity [31].
Mutations in TRPS1 in the current series: TRPS-I
Four patients with features suggestive of TRPS-I (i.e. short
stature, severe BDE with outcarving of the phalangeal
epiphyses, sparse hair, bulbous tip of the nose or pear
shaped nose, long philtrum, thin upper lip, as described in
table 1) were positive for TRPS1 gene mutation: two pa-
tients (PHP08, previously described [33]; and PHP09) car-
ried the recurrent c.2762G >C/p.Arg921Gln mutation and
the remaining two patients each showed a different muta-
tion: c.2830delA/p.Arg944Glyfs*3 in one case (PHP07,
previously described [33]) and c.3159_3160delAAinsT/
p.Lys1053Asnfs* (PHP10) in the other. Although neither
of these has been described previously in the literature,
the cosegregation in other family members (Additional file
4: Table S1) and frameshift characteristics (i.e., they would
lead to truncated proteins if translated) suggested that
they were possibly pathogenic.
Mutations in PTHLH in the current series: BDE with short
stature PTHLH type
The BDE PTHLH type was suspected in two patients
with BDE and advanced bone maturation for their
chronological age. Indeed, two different novel mutations
(c.101+ 3delAAGT, in PHP11 [34] and c.166C>T/
p.Arg56*, in PHP12 [35]) were identified in the PTHLH
gene in these patients. The characteristics of these muta-
tions (frameshift and nonsense, respectively) suggested
that they were causative of the pathology.
Discussion
PHP includes a heterogenic group of rare disorders asso-
ciated with the AHO phenotype [1, 2]. Except for sub-
cutaneous ossifications, the features of AHO are rather
nonspecific as they also appear in other disorders, such
as AHO-like syndrome [8] or acrodysostosis [11–13].Less frequently, misdiagnosis with other entities has
been observed because of the presence of BDE com-
bined with short stature and obesity, which are also typ-
ically associated with other dysmorphic features and
sometimes also with hormonal imbalances [33–37]. In
this constellation of features, obesity or overweight and
short stature could act as confusing factors as both are
nonspecific [5, 33]. In addition, although obesity, intel-
lectual disability, and resistance to several hormones are
still extensively related to AHO, they may not be directly
associated with genetic defects in GNAS [5].
The discovery of new genes implicated in syndromes
with a phenotype similar to AHO, as well as other mo-
lecular mechanisms causative of iPPSD2 (classically
named PHP/PPHP) [38], has been very helpful for estab-
lishing a correct genetic diagnosis for patients diagnosed
with an “AHO-like phenotype” of unknown genetic
cause [11, 14, 17, 33–35, 39], as well as for better de-
scribing the characteristic features of these less common
syndromes. In ours and previously reported experiences
[19, 40], BDE is the most specific and objective feature.
For this reason, it was used as the inclusion criterion in
this study and as a starting point to classify the afore-
mentioned disorders in the previously proposed diagnos-
tic algorithm [19]. It is well known that BDE was
initially described as a variable shortening of the meta-
carpals/metatarsals with a more or less normal length of
the phalanges [41].
As a result of the clinical re-evaluation of this series of
patients, half of them (12/23) could be genetically diag-
nosed (supporting the importance of a good clinical
examination, and the need of multidisciplinary ap-
proaches in the follow-up of these patients) and new
knowledge acquired regarding these pathologies and the
characteristic features detailed below.
We also analysed the features observed in our iPPSD4
(5/12) and iPPSD5 (1/12) patients and other cases
described in the literature and noticed that the skeletal
dysmorphisms (broad face, widely spaced eyes,
maxillonasal hypoplasia, severe and generalized brachy-
dactyly in hands/feet, severe short stature, cone-shaped
epiphyses with early epiphyseal fusion, and advanced
bone age [17, 30]) are very similar in both groups, al-
though the facial dysmorphisms are often more severe in
iPPSD5 [17, 30, 42]. Decreased interpedicular distance
and mental retardation also appear to be more specific
for iPPSD5 [6, 17, 30] since iPPSD4 patients show only
behavioural disorders [30]. Finally, hormone resistance,
which was initially used as a main differential character-
istic to classify the patients with acrodysostosis, seems
not to be as specific as initially appeared because more
exceptions are found as more patients are reported
(PTH resistance was recorded in 76% of iPPSD4 and
27% of iPPSD5 cases in the last review of Elli et al. [17]).
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sistance, and although the iPPSD5 patient (PHP06) ini-
tially presented elevated PTH levels, PTH normalized
after correcting the vitamin D deficiency, which is con-
sistent with secondary hyperparathyroidism [32]. It is
noteworthy that in contrast with the rest of the syn-
dromes reflected in the algorithm, in which brachydac-
tyly is usually not marked until the age of 6 years [39,
40], in acrodysostosis (both iPPSD4 and iPPSD5) the
shortening and cone-shaped epiphyses are manifested
during early childhood [16, 30].
Given the presence of brachydactyly and short stat-
ure, TRPS could be confused with the AHO pheno-
type, especially so if obesity (or overweight) and/or
PTH resistance [37] and another hormone imbalance
(GH deficiency has also been reported in some TRPS
cases [43–47]) appear in the clinical profile, as shown
in our two previously published cases [33] reviewed
here. Keeping in mind all the identified cases in our
series of patients, and comparing with those reported
previously, in our opinion the most characteristic and
illustrative features of TRPS syndrome are: bulbous
tip of the nose (or pear-shaped nose), thin upper lip,
involvement of the phalanges in the brachydactyly
pattern and the typical outcarving of the phalangeal
epiphyses, and sparse, slowly growing scalp hair.
Alterations which lead to the haploinsufficiency in
PTHLH, the gene coding for parathyroid hormone re-
lated protein (PTHrP), have been identified as a cause of
autosomal-dominant BDE in 11 families, two of them
within our series [23, 24, 34, 35, 48, 49]. Although ini-
tially named as “BDE with short stature, PTHLH type”
(OMIM#613382), because it is almost always associated
with short stature [23–25], we have observed in both
PTHLH patients in our series (PHP11 [34] and PHP12
[35]) that this short stature may not manifest until mid-
dle or late childhood. In both these cases, the patients
had normal stature for their age but advanced bone age.
Consequently, they experienced early epiphyseal closure,
an early halt to growth, and their predicted final height
is estimated to be below their target height. Thus, both
the progenitors’ final height and bone age should be
taken into account when determining whether patients
show a height in the lower range of normality.
Overall, our use of a diagnostic algorithm in the
current study has helped to determine the genetic cause
in 12/23 patients with BDE who were clinically misdiag-
nosed as PHP/PPHP. Similarly to the 12 cases solved,
the remaining cases were also classified and studied
using the candidate gene approach guided by the pro-
posed algorithm. However, we did not find any genetic
alterations in the candidate genes studied, possibly due
to some limitations of the study, such as (i) analysis of
putative deletions at PTHLH is lacking; (ii) hand X-raysare missing for four patients, therefore it is difficult to
propose any other potential diagnosis, (iii) although a
large number of genes have been identified as the cause
of BDE in recent years, the genetic cause of some BDE
cases remains unknown [50].
Conclusions
We conclude that use of the presented algorithm in pa-
tients with idiopathic BDE is helpful for establishing a
correct genetic diagnosis for those patients who have
been misdiagnosed as PHP/PPHP. [5]
Additional files
Additional file 1:Figure S1. Figure S1. Hand X-rays for patients with
acrodysostosis, caused by mutation at either PRKAR1A (PHP02, panel A) or
PDE4D (PHP06, panel B) They presented severe shortening of all hand
bones with cone-shaped epiphysis (rows). (TIFF 1641 kb)
Additional file 2: Figure S2. Hand X-rays for a mother (PHP09, panel A)
and her daughter (PHP09-D, panel B) with tricho-rhino-phalangeal
syndrome caused by the same mutation in TRPS1. The mother’s hands
showed severe bilateral shortening of the bone with the characteristic
outcarving of the phalangeal epiphysis (row). However her daughter was
too young to manifest this brachydactyly and outcarving. (TIFF 3376 kb)
Additional file 3: Figure S3. Hand X-rays for patients without genetic
diagnosis: (A) Patient PHP18 exhibits stubby digits and shortening of at
least metacarpals (MT) III-IV; (B) Patient PHP19’s hands show bilateral
shortening of MT IV; (C) Patient PHP20 presents shortening of MT IV and
V; (D) Patient PHP21’s hand reveals bilateral shortening of MT IV and first
telophalanx; (E) Patient PHP22’s hands present bilateral shortening of II
and V mesophalanges (similar to BDA4); (F) Patient PHP23 presents mild
shortening of MT IV and V and clinodactyly of the V digit. (TIFF 3217 kb)
Additional file 4: Table S1. Brief summary of the candidate genes
analysed for each patient and the results. (DOCX 21 kb)
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